JAMA Network
About The Study: Among adults with laboratory-confirmed Clostridioides difficile infection (CDI) with one or more prior CDI episodes in the last six months and those with primary CDI at high risk for recurrence, high-dose VE303 (a novel oral microbiome-directed therapy composed of nonpathogenic, nontoxigenic, commensal strains of Clostridia) prevented recurrent CDI compared with placebo. A larger, phase 3 study is needed to confirm these findings.
Authors: Jeffrey L. Silber, M.D., of Vedanta Biosciences Inc., in Cambridge, Massachusetts, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2023.4314)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
